423 related articles for article (PubMed ID: 32253685)
21. Relationship between FDG-PET and the immune microenvironment in breast cancer.
Kitajima K; Higuchi T; Fujimoto Y; Ishikawa E; Yokoyama H; Komoto H; Inao Y; Yamakado K; Miyoshi Y
Eur J Radiol; 2023 Jan; 158():110661. PubMed ID: 36542934
[TBL] [Abstract][Full Text] [Related]
22. 2-Deoxy-2-[fluorine-18] fluoro-d-glucose uptake on positron emission tomography is associated with programmed death ligand-1 expression in patients with pulmonary adenocarcinoma.
Kaira K; Shimizu K; Kitahara S; Yajima T; Atsumi J; Kosaka T; Ohtaki Y; Higuchi T; Oyama T; Asao T; Mogi A
Eur J Cancer; 2018 Sep; 101():181-190. PubMed ID: 30077123
[TBL] [Abstract][Full Text] [Related]
23. Combining PD-L1 Expression and Standardized Uptake Values in FDG-PET/CT Can Predict Prognosis in Patients With Resectable Non-Small-Cell Lung Cancer.
Miyazawa T; Otsubo K; Sakai H; Kimura H; Chosokabe M; Morikawa K; Furuya N; Marushima H; Kojima K; Mineshita M; Koike J; Saji H
Cancer Control; 2021; 28():10732748211038314. PubMed ID: 34384268
[TBL] [Abstract][Full Text] [Related]
24. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
25.
Mitchell KG; Amini B; Wang Y; Carter BW; Godoy MCB; Parra ER; Behrens C; Villalobos P; Reuben A; Lee JJ; Weissferdt A; Moran CA; Fujimoto J; Sepesi B; Walsh GL; Vaporciyan AA; Hofstetter WL; William WN; Gibbons DL; Wang J; Hwu P; Swisher SG; Piwnica-Worms D; Kadara H; Wistuba II; Heymach JV; Peng W; Cascone T
Cancer Immunol Immunother; 2020 Aug; 69(8):1519-1534. PubMed ID: 32300858
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of tumor PD-L1 expression combined with CD8
Wang Q; Lou W; Di W; Wu X
Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic value of
Togo M; Yokobori T; Shimizu K; Handa T; Kaira K; Sano T; Tsukagoshi M; Higuchi T; Yokoo S; Shirabe K; Oyama T
Br J Cancer; 2020 May; 122(11):1686-1694. PubMed ID: 32238919
[TBL] [Abstract][Full Text] [Related]
28. PD-L1 and CD8 are associated with deficient mismatch repair status in triple-negative and HER2-positive breast cancers.
Hou Y; Nitta H; Parwani AV; Li Z
Hum Pathol; 2019 Apr; 86():108-114. PubMed ID: 30633926
[TBL] [Abstract][Full Text] [Related]
29. Relationship between the expression of PD-1/PD-L1 and
Chen R; Zhou X; Liu J; Huang G
Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):848-854. PubMed ID: 30627815
[TBL] [Abstract][Full Text] [Related]
30. Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from ⁶⁸Ga-RGD PET/CT and ¹⁸F-FDG PET/CT.
Yoon HJ; Kang KW; Chun IK; Cho N; Im SA; Jeong S; Lee S; Jung KC; Lee YS; Jeong JM; Lee DS; Chung JK; Moon WK
Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1534-43. PubMed ID: 24652232
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of Immune Reaction and PD-L1 Expression Using Multiplex Immunohistochemistry in HER2-Positive Breast Cancer: The Association With Response to Anti-HER2 Neoadjuvant Therapy.
Hou Y; Nitta H; Wei L; Banks PM; Parwani AV; Li Z
Clin Breast Cancer; 2018 Apr; 18(2):e237-e244. PubMed ID: 29198959
[TBL] [Abstract][Full Text] [Related]
32. PET/MR in invasive ductal breast cancer: correlation between imaging markers and histological phenotype.
Catalano OA; Horn GL; Signore A; Iannace C; Lepore M; Vangel M; Luongo A; Catalano M; Lehman C; Salvatore M; Soricelli A; Catana C; Mahmood U; Rosen BR
Br J Cancer; 2017 Mar; 116(7):893-902. PubMed ID: 28208155
[TBL] [Abstract][Full Text] [Related]
33. Expression of programmed death ligand-1 (PD-L1) and tumor infiltrating lymphocytes (TILs) in breast carcinoma and their clinical significance.
Mondal SK; Bhattacharya S; Sarkar AP; Saha R
J Cancer Res Ther; 2023 Apr; 19(Supplement):S81-S86. PubMed ID: 37147987
[TBL] [Abstract][Full Text] [Related]
34. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.
Cokmert S; Tanriverdi O; Karapolat I; Demir L; Bayoglu V; Can A; Akyol M; Yilmaz Y; Oktay Tarhan M
J BUON; 2016; 21(6):1410-1418. PubMed ID: 28039701
[TBL] [Abstract][Full Text] [Related]
35. Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis.
Gao ZH; Li CX; Liu M; Jiang JY
BMC Cancer; 2020 Nov; 20(1):1150. PubMed ID: 33238978
[TBL] [Abstract][Full Text] [Related]
36. Usefulness of 18F-FDG uptake with clinicopathologic and immunohistochemical prognostic factors in breast cancer.
Kim BS; Sung SH
Ann Nucl Med; 2012 Feb; 26(2):175-83. PubMed ID: 22139552
[TBL] [Abstract][Full Text] [Related]
37. Association between PD-L1 expression and
Choi YJ; Jo K; Hwang SH; Jeong Y; Lee JY; Kim S; Kim SW; Kim YT; Kang WJ
Ann Nucl Med; 2021 Apr; 35(4):415-420. PubMed ID: 33656683
[TBL] [Abstract][Full Text] [Related]
38. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
[TBL] [Abstract][Full Text] [Related]
39. The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene.
Li Y; Opyrchal M; Yao S; Peng X; Yan L; Jabbour H; Khoury T
Breast Cancer Res Treat; 2018 Jul; 170(2):293-302. PubMed ID: 29524062
[TBL] [Abstract][Full Text] [Related]
40. Correlation of tumor-related immunity with 18F-FDG-PET in pulmonary squamous-cell carcinoma.
Kasahara N; Kaira K; Bao P; Higuchi T; Arisaka Y; Erkhem-Ochir B; Sunaga N; Ohtaki Y; Yajima T; Kosaka T; Oyama T; Yokobori T; Asao T; Nishiyama M; Tsushima Y; Kuwano H; Shimizu K; Mogi A
Lung Cancer; 2018 May; 119():71-77. PubMed ID: 29656756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
